Treatment of chronic gout in adult patients refractory to conventional therapy

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Study Phase: Phase 3
Location: Chicago Clincal Research Institute, 611 W. Roosevelt Rd. Chicago, IL 60607
Study Category: Cardiology

Criteria

  • Age 40 years or older
  •  Have previously experienced a heart attack, stroke, or reduced blood flow to limbs caused by narrowed arteries
  • Currently receiving high-intensity statin (medication that lowers the level of harmful cholesterol in the blood)

Benefits

  • You may be compensated for your time and travel

Apply Now

Full Name(Required)
Enter your email
Gender
Date(Required)
e.g. Email, SMS text, home phone, cell phone

All Studies

Rheumatology
Cardiology
Neurology
Infectious Disease
Diabetes
Vaccines